Suppr超能文献

两种标准化动脉瘤性蛛网膜下腔出血后血管痉挛预防方案的比较分析:一项回顾性试点研究。

Comparative analysis of two standardised protocols for prevention of vasospasm following aneurysmal subarachnoid haemorrhage: A retrospective pilot study.

作者信息

Wendl Kristina, Knebusch Martin, Hörmann Bernhard, Eimer Christian, Borgmann Thomas, Egermann Hannes, Münster Tino

机构信息

From the Department of Anesthesiology and Intensive Care Medicine (KW, MK, BH, TM), Department of Neurosurgery (CE, HE) and Department of Radiology, Neuroradiology and Nuclear Medicine (TB), Krankenhaus Barmherzige Brüder, Regensburg, Germany.

出版信息

Eur J Anaesthesiol Intensive Care. 2025 May 9;4(3):e0073. doi: 10.1097/EA9.0000000000000073. eCollection 2025 Jun.

Abstract

BACKGROUND

Cerebral vasospasm is a major complication after subarachnoid haemorrhage. Yet, no standardised applicable therapy regimen has been established so far. Most previous studies concentrated on comparing single drugs, while fewer holistic therapeutic approaches have been compared.

OBJECTIVE

Our objective was to compare two therapy bundles with different administrations of magnesium, catecholamines, nimodipine and molsidomine, regarding the prevention of cerebral vasospasm and neurological outcome after subarachnoid haemorrhage.

DESIGN

Retrospective design, pilot study.

SETTING

This single-centre trial included 44 patients, 22 patients per group (matched pairs), with aneurysmal subarachnoid haemorrhage treated in the hospital of Barmherzige Brüder in Regensburg, Germany, from 2015 to 2022. Exclusion criteria were known comorbidities, such as severe liver, blood or kidney diseases.

MAIN OUTCOME MEASURES

Incidence of vasospasm, survival and clinical outcome.

RESULTS

The incidence of vasospasms showed no significant difference between group 1 (new therapy bundle) and group 2 (previous standard therapy,  = 0.34), as well as the number of surviving patients. Comparing the clinical outcome measured with the Glasgow Outcome Scale after hospitalisation, no significant difference could be seen. The hospital length of stay, group 1: 23 [16.75 to 25.50] days vs. group 2: 30 [22.5 to 34.5] days,  = 0.004, and the intensive care unit (ICU) length of stay (LOS), group 1: 17.50 [12.75 to 24.00] days vs. group 2: 23.50 [19.75 to 32.50] days,  = 0.012, were significantly shorter in group 1.

CONCLUSION

New therapy bundle has the potential to be more effective than the standard therapy method. As a retrospective pilot study with a small sample size, this research may serve as a valuable foundation for future larger prospective studies for better comparison of the different therapeutic approaches.

摘要

背景

脑血管痉挛是蛛网膜下腔出血后的主要并发症。然而,目前尚未建立标准化的适用治疗方案。以往大多数研究集中在比较单一药物,而比较整体治疗方法的研究较少。

目的

我们的目的是比较两种治疗方案,这两种方案在镁、儿茶酚胺、尼莫地平和莫西多明的给药方式上有所不同,比较其在预防蛛网膜下腔出血后脑血管痉挛和神经功能结局方面的效果。

设计

回顾性设计,试点研究。

背景

这项单中心试验纳入了44例患者,每组22例(配对),这些患者均为2015年至2022年在德国雷根斯堡慈善兄弟医院接受治疗的动脉瘤性蛛网膜下腔出血患者。排除标准为已知的合并症,如严重的肝脏、血液或肾脏疾病。

主要观察指标

血管痉挛的发生率、生存率和临床结局。

结果

第1组(新治疗方案)和第2组(先前的标准治疗方案,=0.34)之间的血管痉挛发生率以及存活患者数量均无显著差异。比较住院后用格拉斯哥预后量表测量的临床结局,未见显著差异。住院时间,第1组:23 [16.75至25.50]天,第2组:30 [22.5至34.5]天,=0.004;重症监护病房(ICU)住院时间(LOS),第1组:17.50 [12.75至24.00]天,第2组:23.50 [19.75至32.50]天,=0.012,第1组显著更短。

结论

新治疗方案可能比标准治疗方法更有效。作为一项样本量较小的回顾性试点研究,本研究可为未来规模更大的前瞻性研究提供有价值的基础,以便更好地比较不同的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f58/12122171/ee9e50e4b4cb/ejaic-4-e0073-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验